Certain Environmental Chemicals May Increase CKD Risk
In a study, researchers identified 7 chemicals associated with an increased risk for chronic kidney disease.
Chronic Kidney Disease (CKD)
CHRONIC KIDNEY DISEASE (CKD)
Recovery From Metabolic Syndrome Reduces CKD Risk
Compared with individuals with chronic metabolic syndrome (MetS), those who recovered from preexisting MetS had significant 16% decreased odds of chronic kidney disease, a study found.
Hyperuricemia and Kidney Disease May Be Predictors of Subsequent Flares in Patients With Gout
Researchers examined the changes in the presentation of incident gout in the last20 years and determined risk for subsequent gout flares after an initial gout attack.
Study Explores Outcomes Valued by Glomerular Disease Patients
Highly ranked outcomes for patients and caregivers include kidney function, survival, but also fatigue.
SGLT2 Inhibitors Linked With Lower Risk for Serious Renal Events
Study findings further support the use of SGLT2 inhibitors in a broad range of patients with type 2 diabetes, according to investigators.
Adults Hospitalized for COVID-19 Span Wide Age Range, Study Finds
Investigators who studied hospital admissions for COVID-19 at an integrated health care system in California found that adults across all age groups required inpatient care, not just the elderly, according to a new report in the Journal of the American Medical Association. The report provides details of the clinical manifestation of the disease and characteristics…
Opioids More Harmful Than NSAIDs in Chronic Kidney Disease
Compared with nonsteroidal anti-inflammatory drugs, opioids are more likely to result in adverse kidney outcomes and death, a study found.
Chronic Kidney Disease Risk Lower in Coffee Drinkers
A recent meta-analysis found a significant 13% decreased risk of incident chronic kidney disease among coffee drinkers compared with nondrinkers.
Housing Insecurity May Increase Risk for Incident Kidney Disease
Housing insecurity linked to higher risk for developing albuminuria.
Dapagliflozin To Be Evaluated in COVID-19 Patients With Cardiovascular, Metabolic, or Renal Risk Factors
A phase 3 trial to evaluate dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, as a potential treatment for patients hospitalized with coronavirus disease 2019.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Kidney Disease (CKD)
